`Advancing Inflammatory Bowel Disease Management

CE / CME

Advancing Inflammatory Bowel Disease Management With Precision Medicine and Emerging Data

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: May 08, 2025

Expiration: May 07, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 28-yr-old man with moderate to severe ulcerative colitis is being managed with a treat-to-target approach. He was recently started on a biologic agent and reports improvement in symptoms over the past 6 wk. His partial Mayo score has decreased, but his HCP is concerned about achieving long-term disease control based on STRIDE-II recommendations. According to treat-to-target strategies in IBD, which of the following biomarkers would be most appropriate to assess objective disease control at this stage of therapy?

2.

A 26-yr-old man with ileocolonic Crohn’s disease is in clinical remission on adalimumab maintenance therapy. At his follow-up visit, he reports no symptoms, and his last colonoscopy 8 mo ago showed mucosal healing. The gastroenterologist is following a treat-to-target strategy and aims to monitor for sustained remission. According to consensus and guideline recommendations, which of the following is the most appropriate monitoring strategy for this patient?

3.

How confident are you in your ability to evaluate and apply emerging clinical evidence supporting TL1A blockade as a therapeutic strategy in IBD?